rezpegaldesleukin
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 23, 2023 (NCT06136741)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-2Supplementation
IL2 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095458 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07142252 | Phase 2 | Nov 13, 2025 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT06340360 | Phase 2 | Apr 2, 2024 | Nektar Therapeutics |
| NCT06136741 | Phase 2 | Oct 23, 2023 | Nektar Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nektar Therapeutics | For profit | 2 | 2 | 1 | 2023 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1